Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-021-84733-5 http://scihub22266oqcxt.onion/10.1038/s41598-021-84733-5 33692457!7946899!33692457     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2021 ; 11 (1): 5563 Nephropedia Template TP {{tp|p=33692457|t=2021. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma |pdf=|usr=}}{{33692457}} gab.com Text Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33692457 #FOAvip While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required. Twit Text FOAVip Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33692457 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33692457 #FOAvip English Wikipedia <ref>{{Cite pmid|33692457}}</ref> Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma #MMPMID33692457 Maeda K; Higashi-Kuwata N; Kinoshita N; Kutsuna S; Tsuchiya K; Hattori SI; Matsuda K; Takamatsu Y; Gatanaga H; Oka S; Sugiyama H; Ohmagari N; Mitsuya H Sci Rep 2021[Mar]; 11 (1): 5563 PMID33692457show ga While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/immunology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/*immunology/prevention & control/*therapy[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive/methods[MESH] |Immunoglobulin G/*immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics/prevention & control[MESH] |Plasma/chemistry[MESH] |Receptors, Virus/metabolism[MESH]Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasm(epmc).pdf DeepDyve Pubget Overpricing